



SMERA RATINGS LIMITED

Adani Pharmachem Private Limited (APPL)

*Rating
Rationale*

May 19, 2016

Facilities	Amount (Rs. Crore)	Ratings
Cash Credit*	3.50	SMERA BB+/Stable (Reaffirmed; (Enhanced from Rs. 3.00 crore)
Term Loan	0.22	SMERA BB+/Stable (Reaffirmed)
Term Loan	0.17	SMERA BB+/Stable (Assigned)
FDBN/FDBP/FDBD	3.50	SMERA A4+ (Reaffirmed)
Letter of Credit	10.00	SMERA A4+ (Reaffirmed)
Bank Guarantee	0.05	SMERA A4+ (Reaffirmed)

**Interchangeable with Packing Credit Limit*

SMERA has reaffirmed the long-term rating of '**SMERA BB+**' (read as **SMERA double B plus**) and short term rating of '**SMERA A4+**' (read as **SMERA A four plus**) on the Rs.16.77 crore bank facilities and assigned long term rating of '**SMERA BB+**' (read as **SMERA double B plus**) on the Rs.0.67 crore bank facilities of Adani Pharmachem Private Limited (APPL). The outlook is '**Stable**'. The ratings continue to draw comfort from the experienced management, comfortable financial risk profile and efficient working capital management. However the ratings are constrained by the company's moderate-scale of operations in an intensely competitive segment of the pharmaceutical industry. The ratings note that the profit margins are susceptible to raw material price volatility and forex fluctuation risk.

Updates

APPL's revenues increased marginally in FY2015 at Rs.53.99 crore compared to Rs.49.88 crore in FY2014. Further operating margins have improved in FY2015 at 5.50 per cent compared to 4.90 per cent in FY2014. The financial risk profile remained comfortable with debt to equity ratio at 0.25 times as on March 31, 2015 (considering unsecured loan as quasi-equity) and the interest coverage ratio at 4.25 times for FY2015. APPL's working capital cycle stood comfortable at 58 days in FY2015.

Rating Sensitivity Factors

- Sustainable and substantial increase in revenues
- Sustenance of existing financial risk profile with healthy capital structure

Disclaimer: A SMERA rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. SMERA ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, SMERA, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. SMERA is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. SMERA ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website (www.smera.in) for the latest information on any instrument rated by SMERA.



SMERA RATINGS LIMITED

Adani Pharmachem Private Limited (APPL)

**Rating
Rationale**

Outlook: Stable

SMERA believes APPL will maintain a stable business risk profile over the medium term. The company will continue to benefit from its experienced management and comfortable financial risk profile. The outlook may be revised to 'Positive' if the company registers substantial growth in revenue while achieving sustained improvement in profit margins. Conversely, the outlook may be revised to 'Negative' in case of decline in the profit margins, or deterioration in the financial risk profile or working capital management.

About the Company

APPL (the erstwhile Adani Pharmachem), established in 1981 was converted into a private limited company in 1999. The company undertakes manufacturing and export of bulk drugs and fine chemicals. It derives ~50 per cent of its revenue from exports to Vietnam, Indonesia, Brazil among others. The company's manufacturing unit is located at Rajkot, Gujarat.

For FY2014-15, APPL reported profit after tax (PAT) of Rs.1.17 crore on operating income of Rs.53.99 crore, as compared with PAT of Rs.1.05 crore on operating income of Rs.49.88 crore in FY2013-14.

Contact List:

Media/Business Development	Analytical Contact	Rating Desk
Suman M National Sales Head – Emerging Corporate Group Tel: +91-22-6714 1151 Cell: +91 9892306888 Email: suman.m@smera.in Web: www.smera.in	Mohit Jain Vice President – Rating Operations Tel: +91-22-6714 1105 Email: mohit.jain@smera.in	Tel: +91-22-6714 1184 Email: ratingdesk@smera.in

Disclaimer: A SMERA rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. SMERA ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, SMERA, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. SMERA is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. SMERA ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website (www.smera.in) for the latest information on any instrument rated by SMERA.